Literature DB >> 11239577

Arylamine N-acetyltransferases - of mice, men and microorganisms.

A Upton1, N Johnson, J Sandy, E Sim.   

Abstract

Arylamine N-acetyltransferases (NATs) catalyse the transfer of an acetyl group from acetyl CoA to the terminal nitrogen of hydrazine and arylamine drugs and carcinogens. These enzymes are polymorphic and have an important place in the history of pharmacogenetics, being first identified as responsible for the polymorphic inactivation of the anti-tubercular drug isoniazid. NAT has recently been identified within Mycobacterium tuberculosis itself and is an important candidate for modulating the response of mycobacteria to isoniazid. The first three-dimensional structure of the unique NAT family shows the active-site cysteine to be aligned with conserved histidine and aspartate residues to form a catalytic triad, thus providing an activation mechanism for transfer of the acetyl group from acetyl CoA to cysteine. The unique fold could allow different members of the NAT family to play a variety of roles in endogenous and xenobiotic metabolism.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11239577     DOI: 10.1016/s0165-6147(00)01639-4

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  19 in total

1.  Expression, purification, characterization and structure of Pseudomonas aeruginosa arylamine N-acetyltransferase.

Authors:  Isaac M Westwood; Simon J Holton; Fernando Rodrigues-Lima; Jean-Marie Dupret; Sanjib Bhakta; Martin E M Noble; Edith Sim
Journal:  Biochem J       Date:  2005-01-15       Impact factor: 3.857

2.  Deciphering the ancient and complex evolutionary history of human arylamine N-acetyltransferase genes.

Authors:  Etienne Patin; Luis B Barreiro; Pardis C Sabeti; Frédéric Austerlitz; Francesca Luca; Antti Sajantila; Doron M Behar; Ornella Semino; Anavaj Sakuntabhai; Nicole Guiso; Brigitte Gicquel; Ken McElreavey; Rosalind M Harding; Evelyne Heyer; Lluis Quintana-Murci
Journal:  Am J Hum Genet       Date:  2006-01-13       Impact factor: 11.025

Review 3.  A meta-analysis of the NAT1 and NAT2 polymorphisms and prostate cancer: a huge review.

Authors:  Chunming Gong; Xueying Hu; Yong Gao; Yunfei Cao; Feng Gao; Zengnan Mo
Journal:  Med Oncol       Date:  2010-01-23       Impact factor: 3.064

4.  Kinetic and chemical mechanism of arylamine N-acetyltransferase from Mycobacterium tuberculosis.

Authors:  Alison L Sikora; Brenda A Frankel; John S Blanchard
Journal:  Biochemistry       Date:  2008-09-17       Impact factor: 3.162

5.  Study of NAT2 genetic polymorphism in West African subjects: example of an healthy non-smoker Senegalese population.

Authors:  A Touré; C Diop; M Cabral; M Fall; M Lhermitte; A Diouf; F Broly; D Allorge
Journal:  Mol Biol Rep       Date:  2012-10-07       Impact factor: 2.316

6.  Over-expression, purification, and characterization of recombinant human arylamine N-acetyltransferase 1.

Authors:  Haiqing Wang; Gregory M Vath; Akane Kawamura; Caleb A Bates; Edith Sim; Patrick E Hanna; Carston R Wagner
Journal:  Protein J       Date:  2005-02       Impact factor: 2.371

7.  Expression of folate pathway genes in the cartilage of Hoxd4 and Hoxc8 transgenic mice.

Authors:  Claudia Kruger; Catherine Talmadge; Claudia Kappen
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2006-04

Review 8.  Mechanisms of NSAID-induced hepatotoxicity: focus on nimesulide.

Authors:  Urs A Boelsterli
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

9.  Water-soluble mmp-9 inhibitor prodrug generates active metabolites that cross the blood-brain barrier.

Authors:  Wei Song; Zhihong Peng; Major Gooyit; Mark A Suckow; Valerie A Schroeder; William R Wolter; Mijoon Lee; Masajiro Ikejiri; Jiankun Cui; Zezong Gu; Mayland Chang
Journal:  ACS Chem Neurosci       Date:  2013-05-30       Impact factor: 4.418

10.  Haplotype of N-acetyltransferase 1 and 2 and risk of pancreatic cancer.

Authors:  Li Jiao; Mark A Doll; David W Hein; Melissa L Bondy; Manal M Hassan; James E Hixson; James L Abbruzzese; Donghui Li
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-11       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.